These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 21645575

  • 1. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.
    Vaccine; 2011 Jul 26; 29(33):5421-3. PubMed ID: 21645575
    [Abstract] [Full Text] [Related]

  • 2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 3. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U, Wongsurakiat P, Pooruk P, Maranetra N, Puthavathana P.
    Viral Immunol; 2010 Jun 25; 23(3):329-34. PubMed ID: 20565296
    [Abstract] [Full Text] [Related]

  • 4. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 25; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 5. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 23; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 7. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition.
    Yamashita A, Kawashita N, Kubota-Koketsu R, Inoue Y, Watanabe Y, Ibrahim MS, Ideno S, Yunoki M, Okuno Y, Takagi T, Yasunaga T, Ikuta K.
    Biochem Biophys Res Commun; 2010 Mar 19; 393(4):614-8. PubMed ID: 20152806
    [Abstract] [Full Text] [Related]

  • 8. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J.
    Antiviral Res; 2010 May 19; 86(2):180-7. PubMed ID: 20153776
    [Abstract] [Full Text] [Related]

  • 9. Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice.
    Fang J, Chen Z, Liu X, Li H, Wang J, Shen X, Chen W, Liu Y, Wang Y, Zhao P, Qi Z.
    J Virol Methods; 2011 May 19; 173(2):314-9. PubMed ID: 21392537
    [Abstract] [Full Text] [Related]

  • 10. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA.
    J Virol; 2017 Oct 15; 91(20):. PubMed ID: 28768855
    [Abstract] [Full Text] [Related]

  • 11. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
    Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, Li Y, Wang X, Ge J, Bu Z, Chen H.
    Antiviral Res; 2007 Sep 15; 75(3):234-41. PubMed ID: 17451817
    [Abstract] [Full Text] [Related]

  • 12. Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies.
    Rimmelzwaan GF, Verburgh RJ, Nieuwkoop NJ, Bestebroer TM, Fouchier RA, Osterhaus AD.
    Vaccine; 2011 Apr 18; 29(18):3424-30. PubMed ID: 21396410
    [Abstract] [Full Text] [Related]

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T, Isoda N, Soda K, Sakamoto R, Saijo K, Hagiwara J, Kokumai N, Ohgitani T, Imamura T, Sawata A, Lin Z, Sakoda Y, Kida H.
    Jpn J Vet Res; 2009 Feb 10; 56(4):189-98. PubMed ID: 19358446
    [Abstract] [Full Text] [Related]

  • 15. Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1.
    Zhang R, Rong X, Pan W, Peng T.
    Scand J Infect Dis; 2011 Mar 10; 43(3):216-20. PubMed ID: 21142624
    [Abstract] [Full Text] [Related]

  • 16. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 18. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
    Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J.
    J Med Virol; 2007 Mar 15; 79(3):320-5. PubMed ID: 17245715
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
    Heldens JG, Glansbeek HL, Hilgers LA, Haenen B, Stittelaar KJ, Osterhaus AD, van den Bosch JF.
    Vaccine; 2010 Nov 29; 28(51):8125-31. PubMed ID: 20950729
    [Abstract] [Full Text] [Related]

  • 20. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC.
    Vaccine; 2008 Aug 05; 26(33):4160-7. PubMed ID: 18599164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.